JP2010507619A - オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用 - Google Patents
オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用 Download PDFInfo
- Publication number
- JP2010507619A JP2010507619A JP2009533834A JP2009533834A JP2010507619A JP 2010507619 A JP2010507619 A JP 2010507619A JP 2009533834 A JP2009533834 A JP 2009533834A JP 2009533834 A JP2009533834 A JP 2009533834A JP 2010507619 A JP2010507619 A JP 2010507619A
- Authority
- JP
- Japan
- Prior art keywords
- oxadiazol
- phenyl
- pyridine
- pyridin
- benzonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title abstract description 18
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title abstract description 18
- 150000004867 thiadiazoles Chemical class 0.000 title abstract description 7
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 141
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 85
- 208000035475 disorder Diseases 0.000 claims abstract description 46
- 201000010099 disease Diseases 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 208000002193 Pain Diseases 0.000 claims abstract description 32
- 230000036407 pain Effects 0.000 claims abstract description 32
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract description 10
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 8
- 230000016160 smooth muscle contraction Effects 0.000 claims abstract description 7
- -1 methylenedioxy Chemical group 0.000 claims description 266
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 67
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 61
- 125000004076 pyridyl group Chemical group 0.000 claims description 59
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 51
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000002541 furyl group Chemical group 0.000 claims description 31
- 125000001544 thienyl group Chemical group 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 26
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 23
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 23
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 125000000335 thiazolyl group Chemical group 0.000 claims description 15
- CGPWBGBIDZEQTL-UHFFFAOYSA-N 2-nitropropanedinitrile Chemical compound [O-][N+](=O)C(C#N)C#N CGPWBGBIDZEQTL-UHFFFAOYSA-N 0.000 claims description 14
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 13
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 13
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229960002715 nicotine Drugs 0.000 claims description 11
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 8
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 8
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 7
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000032841 Bulimia Diseases 0.000 claims description 6
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 6
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- 208000013403 hyperactivity Diseases 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 claims description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 206010015037 epilepsy Diseases 0.000 claims description 5
- 206010027175 memory impairment Diseases 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 206010002660 Anoxia Diseases 0.000 claims description 4
- 241000976983 Anoxia Species 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 4
- 208000004983 Phantom Limb Diseases 0.000 claims description 4
- 206010056238 Phantom pain Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 208000005107 Premature Birth Diseases 0.000 claims description 4
- 206010036590 Premature baby Diseases 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000007953 anoxia Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 206010036596 premature ejaculation Diseases 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 201000004700 rosacea Diseases 0.000 claims description 4
- 230000001052 transient effect Effects 0.000 claims description 4
- OGVLEPMNNPZAPS-UHFFFAOYSA-N 2,3-difluoropyridine Chemical compound FC1=CC=CN=C1F OGVLEPMNNPZAPS-UHFFFAOYSA-N 0.000 claims description 3
- CMBQUXUTASICGB-UHFFFAOYSA-N 2-(2-fluorophenyl)-5-(1,2-oxazol-5-yl)-1,3,4-oxadiazole Chemical compound FC1=CC=CC=C1C1=NN=C(C=2ON=CC=2)O1 CMBQUXUTASICGB-UHFFFAOYSA-N 0.000 claims description 3
- FMUZLAFJNMYTHG-UHFFFAOYSA-N 2-(3-bromo-4-methylphenyl)-5-(3-fluorophenyl)-1,3,4-oxadiazole Chemical compound C1=C(Br)C(C)=CC=C1C1=NN=C(C=2C=C(F)C=CC=2)O1 FMUZLAFJNMYTHG-UHFFFAOYSA-N 0.000 claims description 3
- ICIAAVLVGRIDNJ-UHFFFAOYSA-N 2-(3-bromo-4-methylphenyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole Chemical compound C1=C(Br)C(C)=CC=C1C1=NN=C(C=2C=CC(Cl)=CC=2)O1 ICIAAVLVGRIDNJ-UHFFFAOYSA-N 0.000 claims description 3
- YFJBOQRYJSWGEH-UHFFFAOYSA-N 2-(3-fluorophenyl)-5-(2-fluoropyridin-3-yl)-1,3,4-oxadiazole Chemical compound FC1=CC=CC(C=2OC(=NN=2)C=2C(=NC=CC=2)F)=C1 YFJBOQRYJSWGEH-UHFFFAOYSA-N 0.000 claims description 3
- QKKPQJPBWLDVJD-UHFFFAOYSA-N 2-(5-bromofuran-2-yl)-5-pyridin-3-yl-1,3,4-oxadiazole Chemical compound O1C(Br)=CC=C1C1=NN=C(C=2C=NC=CC=2)O1 QKKPQJPBWLDVJD-UHFFFAOYSA-N 0.000 claims description 3
- JCXAVCOMFWLXIB-UHFFFAOYSA-N 2-(5-chloro-2,4-dimethoxyphenyl)-5-(5-methyl-1,2-oxazol-3-yl)-1,3,4-oxadiazole Chemical compound C1=C(Cl)C(OC)=CC(OC)=C1C1=NN=C(C2=NOC(C)=C2)O1 JCXAVCOMFWLXIB-UHFFFAOYSA-N 0.000 claims description 3
- QEJMFUNQZXAFGU-UHFFFAOYSA-N 2-(furan-2-yl)-5-pyrazin-2-ylsulfanyl-1,3,4-oxadiazole Chemical compound C=1N=CC=NC=1SC(O1)=NN=C1C1=CC=CO1 QEJMFUNQZXAFGU-UHFFFAOYSA-N 0.000 claims description 3
- QZVPHPKVKZTFPM-UHFFFAOYSA-N 2-[3-(5-pyridin-3-yl-1,3,4-oxadiazol-2-yl)phenyl]acetonitrile Chemical compound N#CCC1=CC=CC(C=2OC(=NN=2)C=2C=NC=CC=2)=C1 QZVPHPKVKZTFPM-UHFFFAOYSA-N 0.000 claims description 3
- XAKQOYXXHZMWNN-UHFFFAOYSA-N 2-[3-[5-(2,5,6-trifluoropyridin-3-yl)-1,3,4-oxadiazol-2-yl]phenyl]acetonitrile Chemical compound N1=C(F)C(F)=CC(C=2OC(=NN=2)C=2C=C(CC#N)C=CC=2)=C1F XAKQOYXXHZMWNN-UHFFFAOYSA-N 0.000 claims description 3
- NPDRAXXZRVVTTH-UHFFFAOYSA-N 2-[3-[5-(6-chloropyridin-3-yl)-1,3,4-oxadiazol-2-yl]phenyl]acetonitrile Chemical compound C1=NC(Cl)=CC=C1C1=NN=C(C=2C=C(CC#N)C=CC=2)O1 NPDRAXXZRVVTTH-UHFFFAOYSA-N 0.000 claims description 3
- QPWKRWCXDWHYKQ-UHFFFAOYSA-N 2-[3-[5-(6-fluoropyridin-3-yl)-1,3,4-oxadiazol-2-yl]phenyl]acetonitrile Chemical compound C1=NC(F)=CC=C1C1=NN=C(C=2C=C(CC#N)C=CC=2)O1 QPWKRWCXDWHYKQ-UHFFFAOYSA-N 0.000 claims description 3
- JRPLIJNANQAYSD-UHFFFAOYSA-N 2-benzylsulfanyl-5-pyridin-3-yl-1,3,4-oxadiazole Chemical compound C=1C=CC=CC=1CSC(O1)=NN=C1C1=CC=CN=C1 JRPLIJNANQAYSD-UHFFFAOYSA-N 0.000 claims description 3
- JWWYYSYRQLPOPE-UHFFFAOYSA-N 3-(5-pyridin-3-yl-1,3,4-thiadiazol-2-yl)benzonitrile Chemical compound N#CC1=CC=CC(C=2SC(=NN=2)C=2C=NC=CC=2)=C1 JWWYYSYRQLPOPE-UHFFFAOYSA-N 0.000 claims description 3
- VXCYUKZOXHXTAZ-UHFFFAOYSA-N 3-[5-(3-cyanophenyl)-1,3,4-thiadiazol-2-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2SC(=NN=2)C=2C=C(C=CC=2)C#N)=C1 VXCYUKZOXHXTAZ-UHFFFAOYSA-N 0.000 claims description 3
- WSOJVCHQNJGEOS-UHFFFAOYSA-N 4-chloro-2-[5-[2-chloro-5-(trifluoromethyl)phenyl]-1,3,4-thiadiazol-2-yl]phenol Chemical compound OC1=CC=C(Cl)C=C1C1=NN=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)S1 WSOJVCHQNJGEOS-UHFFFAOYSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000026097 Factitious disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- 241000208125 Nicotiana Species 0.000 claims description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010034912 Phobia Diseases 0.000 claims description 3
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 206010052276 Pseudodementia Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 229940049706 benzodiazepine Drugs 0.000 claims description 3
- 150000001557 benzodiazepines Chemical class 0.000 claims description 3
- 208000028683 bipolar I disease Diseases 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 229960002069 diamorphine Drugs 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010013932 dyslexia Diseases 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 201000009863 inflammatory diarrhea Diseases 0.000 claims description 3
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 3
- 229960005181 morphine Drugs 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 201000003631 narcolepsy Diseases 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 208000019899 phobic disease Diseases 0.000 claims description 3
- 230000020341 sensory perception of pain Effects 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- NSFPLERJOCIKME-UHFFFAOYSA-N 5-(5-pyridin-3-yl-1,3,4-thiadiazol-2-yl)thiophene-2-carbonitrile Chemical compound S1C(C#N)=CC=C1C1=NN=C(C=2C=NC=CC=2)S1 NSFPLERJOCIKME-UHFFFAOYSA-N 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000009849 deactivation Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 240000004308 marijuana Species 0.000 claims description 2
- UIZYWRLCIJJRGB-UHFFFAOYSA-N n-(5-benzylsulfonyl-1,3,4-thiadiazol-2-yl)acetamide Chemical compound S1C(NC(=O)C)=NN=C1S(=O)(=O)CC1=CC=CC=C1 UIZYWRLCIJJRGB-UHFFFAOYSA-N 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 102000034337 acetylcholine receptors Human genes 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000029849 luteinization Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract description 11
- 210000001428 peripheral nervous system Anatomy 0.000 abstract description 10
- 230000001713 cholinergic effect Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 208000030172 endocrine system disease Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 125000005843 halogen group Chemical group 0.000 description 33
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 9
- 150000004866 oxadiazoles Chemical class 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 201000009032 substance abuse Diseases 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- UYXBRSTWDVSSMY-UHFFFAOYSA-N n'-(3-cyanobenzoyl)pyridine-3-carbohydrazide Chemical compound C=1C=CN=CC=1C(=O)NNC(=O)C1=CC=CC(C#N)=C1 UYXBRSTWDVSSMY-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 102000009660 Cholinergic Receptors Human genes 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- VRXNFXWJYIXSNC-UHFFFAOYSA-N ethyl 5-chloro-2,4-dimethoxybenzoate Chemical compound CCOC(=O)C1=CC(Cl)=C(OC)C=C1OC VRXNFXWJYIXSNC-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- CXGNGMANBKYIEF-UHFFFAOYSA-N n-(5-benzylsulfanyl-1,3,4-thiadiazol-2-yl)acetamide Chemical compound S1C(NC(=O)C)=NN=C1SCC1=CC=CC=C1 CXGNGMANBKYIEF-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- KFUSANSHCADHNJ-UHFFFAOYSA-N pyridine-3-carbohydrazide Chemical compound NNC(=O)C1=CC=CN=C1 KFUSANSHCADHNJ-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- FLWVAHBGRKYNEE-UHFFFAOYSA-N 2-sulfanyl-3h-oxadiazole Chemical compound SN1NC=CO1 FLWVAHBGRKYNEE-UHFFFAOYSA-N 0.000 description 2
- KYKPMNVLZRQRHZ-UHFFFAOYSA-N 3-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC(C#N)=C1 KYKPMNVLZRQRHZ-UHFFFAOYSA-N 0.000 description 2
- GYLKKXHEIIFTJH-UHFFFAOYSA-N 3-cyanobenzoic acid Chemical compound OC(=O)C1=CC=CC(C#N)=C1 GYLKKXHEIIFTJH-UHFFFAOYSA-N 0.000 description 2
- YVMAOAQQUJFELI-UHFFFAOYSA-N 5-chloro-2,4-dimethoxybenzoic acid Chemical compound COC1=CC(OC)=C(C(O)=O)C=C1Cl YVMAOAQQUJFELI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- 208000025569 Tobacco Use disease Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000001856 erectile effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- ZICMAYXKFVAJBL-UHFFFAOYSA-N n'-(3-cyanobenzoyl)-2,5,6-trifluoropyridine-3-carbohydrazide Chemical compound N1=C(F)C(F)=CC(C(=O)NNC(=O)C=2C=C(C=CC=2)C#N)=C1F ZICMAYXKFVAJBL-UHFFFAOYSA-N 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 1
- ZAEZYPHDZWXOND-UHFFFAOYSA-N 2-bromo-n'-(pyridine-3-carbonyl)-1,3-thiazole-4-carbohydrazide Chemical compound S1C(Br)=NC(C(=O)NNC(=O)C=2C=NC=CC=2)=C1 ZAEZYPHDZWXOND-UHFFFAOYSA-N 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- NZVAKEUHPNPKLM-UHFFFAOYSA-N 2-fluoro-n'-(3-fluorobenzoyl)pyridine-3-carbohydrazide Chemical compound FC1=CC=CC(C(=O)NNC(=O)C=2C(=NC=CC=2)F)=C1 NZVAKEUHPNPKLM-UHFFFAOYSA-N 0.000 description 1
- BTGMYVPZVARZKU-UHFFFAOYSA-N 3-(cyanomethyl)benzohydrazide Chemical compound NNC(=O)C1=CC=CC(CC#N)=C1 BTGMYVPZVARZKU-UHFFFAOYSA-N 0.000 description 1
- KYELWEURJLYKBW-UHFFFAOYSA-N 3-[(pyridine-3-carbonylamino)carbamoyl]benzamide Chemical compound NC(=O)C1=CC=CC(C(=O)NNC(=O)C=2C=NC=CC=2)=C1 KYELWEURJLYKBW-UHFFFAOYSA-N 0.000 description 1
- ZFJOMUKPDWNRFI-UHFFFAOYSA-N 3-bromo-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1Br ZFJOMUKPDWNRFI-UHFFFAOYSA-N 0.000 description 1
- CBVRCSNBYSLDFG-UHFFFAOYSA-N 3-chloro-2-hydroxybenzohydrazide Chemical compound NNC(=O)C1=CC=CC(Cl)=C1O CBVRCSNBYSLDFG-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- HOXSWOKYGXVYNV-UHFFFAOYSA-N 3-cyano-n'-(3-cyanobenzoyl)benzohydrazide Chemical compound C=1C=CC(C#N)=CC=1C(=O)NNC(=O)C1=CC=CC(C#N)=C1 HOXSWOKYGXVYNV-UHFFFAOYSA-N 0.000 description 1
- UUISEXNUHLZEDB-UHFFFAOYSA-N 3-fluorobenzohydrazide Chemical compound NNC(=O)C1=CC=CC(F)=C1 UUISEXNUHLZEDB-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PKBGHORNUFQAAW-UHFFFAOYSA-N 4-chlorobenzohydrazide Chemical compound NNC(=O)C1=CC=C(Cl)C=C1 PKBGHORNUFQAAW-UHFFFAOYSA-N 0.000 description 1
- PJWRZYGGTHXGQO-UHFFFAOYSA-N 4-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=C(C#N)C=C1 PJWRZYGGTHXGQO-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- UUBKWODOINKONV-UHFFFAOYSA-N 5-(furan-2-yl)-3h-1,3,4-oxadiazole-2-thione Chemical compound O1C(S)=NN=C1C1=CC=CO1 UUBKWODOINKONV-UHFFFAOYSA-N 0.000 description 1
- NSFYBTGKHHHQIX-UHFFFAOYSA-N 6-chloro-4,6-dimethoxycyclohexa-2,4-diene-1-carbohydrazide Chemical compound COC1=CC(Cl)(OC)C(C(=O)NN)C=C1 NSFYBTGKHHHQIX-UHFFFAOYSA-N 0.000 description 1
- HQGIFUBUTQKQIM-UHFFFAOYSA-N 6-chloro-n'-(3-cyanobenzoyl)pyridine-3-carbohydrazide Chemical compound C1=NC(Cl)=CC=C1C(=O)NNC(=O)C1=CC=CC(C#N)=C1 HQGIFUBUTQKQIM-UHFFFAOYSA-N 0.000 description 1
- MIXLPINARPENBL-UHFFFAOYSA-N 6-chloro-n'-[4-(cyanomethyl)benzoyl]pyridine-3-carbohydrazide Chemical compound C1=NC(Cl)=CC=C1C(=O)NNC(=O)C1=CC=C(CC#N)C=C1 MIXLPINARPENBL-UHFFFAOYSA-N 0.000 description 1
- BWUXIXWRUXJGPY-UHFFFAOYSA-N 6-fluoro-n'-(4-fluorobenzoyl)pyridine-3-carbohydrazide Chemical compound C1=CC(F)=CC=C1C(=O)NNC(=O)C1=CC=C(F)N=C1 BWUXIXWRUXJGPY-UHFFFAOYSA-N 0.000 description 1
- WXHPYVNOEDALAS-UHFFFAOYSA-N 6-methylpyridine-3-carbohydrazide Chemical compound CC1=CC=C(C(=O)NN)C=N1 WXHPYVNOEDALAS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 0 COc(c(C(NN)=*)c1)cc(OC)c1Cl Chemical compound COc(c(C(NN)=*)c1)cc(OC)c1Cl 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UNUHAXZDYKDOEF-UHFFFAOYSA-N N'-(5-nitrofuran-2-carbonyl)pyridine-3-carbohydrazide Chemical compound [N+](=O)([O-])C1=CC=C(O1)C(=O)NNC(C1=CN=CC=C1)=O UNUHAXZDYKDOEF-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- SKTSVWWOAIAIKI-UHFFFAOYSA-N furan-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CO1 SKTSVWWOAIAIKI-UHFFFAOYSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical group N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- HXZSBZRSCXABKB-UHFFFAOYSA-N n'-(1,3-benzodioxole-5-carbonyl)pyridine-3-carbohydrazide Chemical compound C=1C=C2OCOC2=CC=1C(=O)NNC(=O)C1=CC=CN=C1 HXZSBZRSCXABKB-UHFFFAOYSA-N 0.000 description 1
- KNPGCEMNAIQLHQ-UHFFFAOYSA-N n'-(2-fluorobenzoyl)-1,2-oxazole-5-carbohydrazide Chemical compound FC1=CC=CC=C1C(=O)NNC(=O)C1=CC=NO1 KNPGCEMNAIQLHQ-UHFFFAOYSA-N 0.000 description 1
- GMLQPOJRFJUTIS-UHFFFAOYSA-N n'-(3-cyano-4-methylbenzoyl)pyridine-3-carbohydrazide Chemical compound C1=C(C#N)C(C)=CC=C1C(=O)NNC(=O)C1=CC=CN=C1 GMLQPOJRFJUTIS-UHFFFAOYSA-N 0.000 description 1
- UKKMNAKALBMMHA-UHFFFAOYSA-N n'-(3-cyanobenzoyl)-2,6-difluoropyridine-3-carbohydrazide Chemical compound FC1=NC(F)=CC=C1C(=O)NNC(=O)C1=CC=CC(C#N)=C1 UKKMNAKALBMMHA-UHFFFAOYSA-N 0.000 description 1
- GKMBEQNBHYTKGB-UHFFFAOYSA-N n'-(3-cyanobenzoyl)-2-fluoropyridine-3-carbohydrazide Chemical compound FC1=NC=CC=C1C(=O)NNC(=O)C1=CC=CC(C#N)=C1 GKMBEQNBHYTKGB-UHFFFAOYSA-N 0.000 description 1
- WGVHKEYUWJCQSS-UHFFFAOYSA-N n'-(3-cyanobenzoyl)-6-fluoropyridine-3-carbohydrazide Chemical compound C1=NC(F)=CC=C1C(=O)NNC(=O)C1=CC=CC(C#N)=C1 WGVHKEYUWJCQSS-UHFFFAOYSA-N 0.000 description 1
- MRBKFLYHUMBUMD-UHFFFAOYSA-N n'-(3-cyanobenzoyl)-6-methylpyridine-3-carbohydrazide Chemical compound C1=NC(C)=CC=C1C(=O)NNC(=O)C1=CC=CC(C#N)=C1 MRBKFLYHUMBUMD-UHFFFAOYSA-N 0.000 description 1
- VTQVOYWTSMBOLG-UHFFFAOYSA-N n'-(3-cyanobenzoyl)pyrimidine-5-carbohydrazide Chemical compound C=1C=CC(C#N)=CC=1C(=O)NNC(=O)C1=CN=CN=C1 VTQVOYWTSMBOLG-UHFFFAOYSA-N 0.000 description 1
- SSAUYSKJWMQDNJ-UHFFFAOYSA-N n'-(3-nitrobenzoyl)pyridine-3-carbohydrazide Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)NNC(=O)C=2C=NC=CC=2)=C1 SSAUYSKJWMQDNJ-UHFFFAOYSA-N 0.000 description 1
- ZRPBHRXWVJTKQW-UHFFFAOYSA-N n'-(4-chlorobenzoyl)-2,5,6-trifluoropyridine-3-carbohydrazide Chemical compound N1=C(F)C(F)=CC(C(=O)NNC(=O)C=2C=CC(Cl)=CC=2)=C1F ZRPBHRXWVJTKQW-UHFFFAOYSA-N 0.000 description 1
- QJKZHJTUBATINK-UHFFFAOYSA-N n'-(4-chlorobenzoyl)-2,6-difluoropyridine-3-carbohydrazide Chemical compound FC1=NC(F)=CC=C1C(=O)NNC(=O)C1=CC=C(Cl)C=C1 QJKZHJTUBATINK-UHFFFAOYSA-N 0.000 description 1
- BFTWPOGGFSYYPT-UHFFFAOYSA-N n'-(4-chlorobenzoyl)-2-fluoropyridine-3-carbohydrazide Chemical compound FC1=NC=CC=C1C(=O)NNC(=O)C1=CC=C(Cl)C=C1 BFTWPOGGFSYYPT-UHFFFAOYSA-N 0.000 description 1
- CIFZVBRHPXSEPR-UHFFFAOYSA-N n'-(4-chlorobenzoyl)-6-fluoropyridine-3-carbohydrazide Chemical compound C1=NC(F)=CC=C1C(=O)NNC(=O)C1=CC=C(Cl)C=C1 CIFZVBRHPXSEPR-UHFFFAOYSA-N 0.000 description 1
- YTPHCXDWPYYHRP-UHFFFAOYSA-N n'-(4-cyano-3-methylbenzoyl)pyridine-3-carbohydrazide Chemical compound C1=C(C#N)C(C)=CC(C(=O)NNC(=O)C=2C=NC=CC=2)=C1 YTPHCXDWPYYHRP-UHFFFAOYSA-N 0.000 description 1
- PNNYLYWFIFJVNA-UHFFFAOYSA-N n'-(4-cyanobenzoyl)-2,5,6-trifluoropyridine-3-carbohydrazide Chemical compound N1=C(F)C(F)=CC(C(=O)NNC(=O)C=2C=CC(=CC=2)C#N)=C1F PNNYLYWFIFJVNA-UHFFFAOYSA-N 0.000 description 1
- HDKVFHWRIPGCLM-UHFFFAOYSA-N n'-(4-cyanobenzoyl)-2,6-difluoropyridine-3-carbohydrazide Chemical compound FC1=NC(F)=CC=C1C(=O)NNC(=O)C1=CC=C(C#N)C=C1 HDKVFHWRIPGCLM-UHFFFAOYSA-N 0.000 description 1
- MGDFIKUYHWKEJR-UHFFFAOYSA-N n'-(4-cyanobenzoyl)-2-fluoropyridine-3-carbohydrazide Chemical compound FC1=NC=CC=C1C(=O)NNC(=O)C1=CC=C(C#N)C=C1 MGDFIKUYHWKEJR-UHFFFAOYSA-N 0.000 description 1
- ZDSUBTABXXEQMA-UHFFFAOYSA-N n'-(4-cyanobenzoyl)-6-fluoropyridine-3-carbohydrazide Chemical compound C1=NC(F)=CC=C1C(=O)NNC(=O)C1=CC=C(C#N)C=C1 ZDSUBTABXXEQMA-UHFFFAOYSA-N 0.000 description 1
- SJTFWGXFMAYRNP-UHFFFAOYSA-N n'-(4-cyanobenzoyl)pyridine-3-carbohydrazide Chemical compound C=1C=C(C#N)C=CC=1C(=O)NNC(=O)C1=CC=CN=C1 SJTFWGXFMAYRNP-UHFFFAOYSA-N 0.000 description 1
- MPUWTQNVHSXKDR-UHFFFAOYSA-N n'-(5-bromofuran-2-carbonyl)pyridine-3-carbohydrazide Chemical compound O1C(Br)=CC=C1C(=O)NNC(=O)C1=CC=CN=C1 MPUWTQNVHSXKDR-UHFFFAOYSA-N 0.000 description 1
- JUKMQYQUEUQFOM-UHFFFAOYSA-N n'-(5-bromothiophene-2-carbonyl)-2-fluoropyridine-3-carbohydrazide Chemical compound FC1=NC=CC=C1C(=O)NNC(=O)C1=CC=C(Br)S1 JUKMQYQUEUQFOM-UHFFFAOYSA-N 0.000 description 1
- MRGNWNRBIJSLRM-UHFFFAOYSA-N n'-(5-bromothiophene-2-carbonyl)-6-chloropyridine-3-carbohydrazide Chemical compound C1=NC(Cl)=CC=C1C(=O)NNC(=O)C1=CC=C(Br)S1 MRGNWNRBIJSLRM-UHFFFAOYSA-N 0.000 description 1
- JEDDDTSFKNUWMM-UHFFFAOYSA-N n'-(5-bromothiophene-2-carbonyl)-6-fluoropyridine-3-carbohydrazide Chemical compound C1=NC(F)=CC=C1C(=O)NNC(=O)C1=CC=C(Br)S1 JEDDDTSFKNUWMM-UHFFFAOYSA-N 0.000 description 1
- RCHHPCWHOHNHFU-UHFFFAOYSA-N n'-(5-chloro-2,4-dimethoxybenzoyl)-5-methyl-1,2-oxazole-3-carbohydrazide Chemical compound C1=C(Cl)C(OC)=CC(OC)=C1C(=O)NNC(=O)C1=NOC(C)=C1 RCHHPCWHOHNHFU-UHFFFAOYSA-N 0.000 description 1
- CEPAARSLNHOVID-UHFFFAOYSA-N n'-(5-chlorofuran-2-carbonyl)pyridine-3-carbohydrazide Chemical compound O1C(Cl)=CC=C1C(=O)NNC(=O)C1=CC=CN=C1 CEPAARSLNHOVID-UHFFFAOYSA-N 0.000 description 1
- WVMYUTWIWHCCQA-UHFFFAOYSA-N n'-(5-cyanothiophene-2-carbonyl)pyridine-3-carbohydrazide Chemical compound C=1C=C(C#N)SC=1C(=O)NNC(=O)C1=CC=CN=C1 WVMYUTWIWHCCQA-UHFFFAOYSA-N 0.000 description 1
- XHNRLWZYTYPQMJ-UHFFFAOYSA-N n'-(5-nitrothiophene-2-carbonyl)pyridine-3-carbohydrazide Chemical compound S1C([N+](=O)[O-])=CC=C1C(=O)NNC(=O)C1=CC=CN=C1 XHNRLWZYTYPQMJ-UHFFFAOYSA-N 0.000 description 1
- NMOTVNLNAMIULY-UHFFFAOYSA-N n'-(furan-2-carbonyl)pyridine-3-carbohydrazide Chemical compound C=1C=COC=1C(=O)NNC(=O)C1=CC=CN=C1 NMOTVNLNAMIULY-UHFFFAOYSA-N 0.000 description 1
- BRBCRTWYRUHABC-UHFFFAOYSA-N n'-(furan-3-carbonyl)pyridine-3-carbohydrazide Chemical compound C1=COC=C1C(=O)NNC(=O)C1=CC=CN=C1 BRBCRTWYRUHABC-UHFFFAOYSA-N 0.000 description 1
- BMJAKDPHNYJDIZ-UHFFFAOYSA-N n'-(pyridine-3-carbonyl)-1,2-oxazole-5-carbohydrazide Chemical compound C=1C=NOC=1C(=O)NNC(=O)C1=CC=CN=C1 BMJAKDPHNYJDIZ-UHFFFAOYSA-N 0.000 description 1
- SNQGSFSTKZJNCR-UHFFFAOYSA-N n'-(pyridine-3-carbonyl)pyridine-3-carbohydrazide Chemical compound C=1C=CN=CC=1C(=O)NNC(=O)C1=CC=CN=C1 SNQGSFSTKZJNCR-UHFFFAOYSA-N 0.000 description 1
- VGIWZYKTQFUIAL-UHFFFAOYSA-N n'-[3-(cyanomethyl)benzoyl]-6-fluoropyridine-3-carbohydrazide Chemical compound C1=NC(F)=CC=C1C(=O)NNC(=O)C1=CC=CC(CC#N)=C1 VGIWZYKTQFUIAL-UHFFFAOYSA-N 0.000 description 1
- UKVSEXKQJBISIK-UHFFFAOYSA-N n'-[3-(cyanomethyl)benzoyl]pyridine-3-carbohydrazide Chemical compound C=1C=CN=CC=1C(=O)NNC(=O)C1=CC=CC(CC#N)=C1 UKVSEXKQJBISIK-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940126027 positive allosteric modulator Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85407806P | 2006-10-25 | 2006-10-25 | |
| DKPA200601380 | 2006-10-25 | ||
| PCT/EP2007/061433 WO2008049864A1 (en) | 2006-10-25 | 2007-10-24 | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010507619A true JP2010507619A (ja) | 2010-03-11 |
| JP2010507619A5 JP2010507619A5 (enExample) | 2010-08-05 |
Family
ID=38962931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533834A Abandoned JP2010507619A (ja) | 2006-10-25 | 2007-10-24 | オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100029685A1 (enExample) |
| EP (1) | EP2079734A1 (enExample) |
| JP (1) | JP2010507619A (enExample) |
| AU (1) | AU2007310897A1 (enExample) |
| CA (1) | CA2667545A1 (enExample) |
| IL (1) | IL197397A0 (enExample) |
| MX (1) | MX2009003892A (enExample) |
| NO (1) | NO20091977L (enExample) |
| WO (1) | WO2008049864A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013544792A (ja) * | 2010-10-22 | 2013-12-19 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 殺害虫剤としての新規ヘテロ環式化合物 |
| JP2019500352A (ja) * | 2015-12-10 | 2019-01-10 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病の治療方法 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101597665B1 (ko) | 2007-08-13 | 2016-02-24 | 몬산토 테크놀로지 엘엘씨 | 선충류 방제용 조성물 및 방법 |
| AU2013203849B2 (en) * | 2007-08-13 | 2016-01-14 | Monsanto Technology Llc | Compositions and methods for controlling nematodes |
| GB0723719D0 (en) * | 2007-12-04 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| GB0723815D0 (en) * | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| US8383658B2 (en) | 2008-06-04 | 2013-02-26 | Abbott Laboratories | Isoxazole based neuronal nicotinic receptor ligands and methods of use |
| EP2591674B1 (de) | 2008-07-17 | 2016-01-13 | Bayer CropScience AG | Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel |
| AU2009289329A1 (en) * | 2008-09-02 | 2010-03-11 | Neurosearch A/S | Triazole derivatives and their use as nicotinic acetylcholine receptor modulators |
| ES2754503T3 (es) | 2009-02-10 | 2020-04-17 | Monsanto Technology Llc | Composiciones y procedimientos de lucha contra nematodos |
| US9095596B2 (en) | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| WO2011073299A1 (en) | 2009-12-18 | 2011-06-23 | Neurosearch A/S | Pyridinyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| AU2011252974A1 (en) * | 2010-05-12 | 2012-12-13 | Vanderbilt University | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| JP5826848B2 (ja) | 2010-09-02 | 2015-12-02 | モンサント テクノロジー エルエルシー | 線虫を防除する新規組成物および方法 |
| EP2967065A4 (en) | 2013-03-15 | 2016-08-24 | Monsanto Technology Llc | N-, C-SUBSTITUTED AZOLE FOR COMBATING NEMATODE PENINS |
| CZ305680B6 (cs) * | 2013-04-04 | 2016-02-03 | Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové | Substituovaný diazol, jeho použití a farmaceutický přípravek ho obsahující |
| US10513110B2 (en) * | 2014-06-13 | 2019-12-24 | Electronics For Imaging, Inc. | Integration of a line-scan camera on a single pass inkjet printer |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| BR112022003959A2 (pt) * | 2019-09-05 | 2022-05-24 | Trevena Inc | Métodos para tratamento de epilepsia |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL261797A (enExample) * | 1960-03-01 | |||
| CH411906A (de) * | 1960-03-01 | 1966-04-30 | Ciba Geigy | Verfahren zur Herstellung neuer 1,3,4-Thiadiazole |
| NL287227A (enExample) * | 1961-12-28 | |||
| US3574842A (en) * | 1969-11-10 | 1971-04-13 | American Cyanamid Co | Compositions of 4-(1,2,4-oxadiazole-3 or 5-yl)pyridinium salts and method of lowering blood sugar levels with same |
| US3964896A (en) | 1971-08-09 | 1976-06-22 | Uniroyal, Inc. | Oxadiazole benzoic acid derivatives as herbicides |
| US3947263A (en) * | 1974-07-29 | 1976-03-30 | Uniroyal, Inc. | Plant growth regulants |
| EP0288432A1 (de) * | 1987-04-09 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| FR2636628B1 (fr) * | 1988-08-25 | 1990-12-28 | Sanofi Sa | Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant |
| JP2801269B2 (ja) * | 1989-07-10 | 1998-09-21 | キヤノン株式会社 | 化合物およびこれを含む液晶組成物およびこれを使用した液晶素子 |
| US5670526A (en) * | 1995-12-21 | 1997-09-23 | Otsuka Pharmaceutical Co., Ltd. | 1,3,4-oxadiazoles |
| PL334570A1 (en) * | 1997-01-14 | 2000-03-13 | Egyt Gyogyszervegyeszeti Gyar | Derivatives of 2-(1,2,4-triazol-1-yl)-1,3,4-thiadiazole acting on central nervous system and hearth |
| US6699853B2 (en) * | 1997-06-16 | 2004-03-02 | Hoechst Schering Agrevo Gmbh | 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides |
| DE19725450A1 (de) | 1997-06-16 | 1998-12-17 | Hoechst Schering Agrevo Gmbh | 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AR032653A1 (es) * | 2001-02-09 | 2003-11-19 | Telik Inc | Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos. |
| PL369598A1 (en) * | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CN1638776A (zh) * | 2001-06-08 | 2005-07-13 | 西托维亚公司 | 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物 |
| FR2832712B1 (fr) * | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique |
| FR2832713B1 (fr) * | 2001-11-23 | 2004-02-13 | Sanofi Synthelabo | Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| ATE450263T1 (de) * | 2004-02-04 | 2009-12-15 | Neurosearch As | Diazabicyclische aryl-derivate als cholinerge rezeptor-modulatoren |
| GB0403744D0 (en) * | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| EP2336113A1 (en) * | 2004-05-29 | 2011-06-22 | 7TM Pharma A/S | CRTH2 Receptor Ligands for Medical Use |
| MX2008014887A (es) * | 2006-05-30 | 2008-12-05 | Neurosearch As | Nuevos derivados de 1,4-diaza-biciclo[3.2.2]nonil oxadiazolilo y su uso medico. |
| US20080015193A1 (en) * | 2006-06-20 | 2008-01-17 | Mendoza Jose S | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof |
| EP2044926B1 (en) * | 2006-07-20 | 2018-01-10 | National University Corporation Okayama University | Oral composition for dental purposes |
| BRPI0815490A2 (pt) * | 2007-08-17 | 2017-03-21 | Astrazeneca Ab | composto, composição faramcêutica, método para tratar diabetes mellitus e/ou obesidade em um animal de sangue quente, e, processo para preparar um composto |
| HRP20110449T1 (hr) * | 2007-08-17 | 2011-07-31 | Actelion Pharmaceuticals Ltd. | Derivati piridina kao modulatori receptora s1p1/edg1 |
| MX2010006647A (es) * | 2007-12-26 | 2010-08-17 | Sanofi Aventis | Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos. |
| BRPI0914978A2 (pt) * | 2008-06-09 | 2015-10-27 | Sanofi Aventis | sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos |
| WO2010117662A1 (en) * | 2009-03-30 | 2010-10-14 | Exelixis, Inc. | Modulators of s1p and methods of making and using |
| SA110310332B1 (ar) * | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
-
2007
- 2007-10-24 JP JP2009533834A patent/JP2010507619A/ja not_active Abandoned
- 2007-10-24 WO PCT/EP2007/061433 patent/WO2008049864A1/en not_active Ceased
- 2007-10-24 CA CA002667545A patent/CA2667545A1/en not_active Abandoned
- 2007-10-24 EP EP07821796A patent/EP2079734A1/en not_active Withdrawn
- 2007-10-24 US US12/447,205 patent/US20100029685A1/en not_active Abandoned
- 2007-10-24 MX MX2009003892A patent/MX2009003892A/es not_active Application Discontinuation
- 2007-10-24 AU AU2007310897A patent/AU2007310897A1/en not_active Abandoned
-
2009
- 2009-03-04 IL IL197397A patent/IL197397A0/en unknown
- 2009-05-20 NO NO20091977A patent/NO20091977L/no not_active Application Discontinuation
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013544792A (ja) * | 2010-10-22 | 2013-12-19 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 殺害虫剤としての新規ヘテロ環式化合物 |
| US9173396B2 (en) | 2010-10-22 | 2015-11-03 | Bayer Intellectual Property Gmbh | Heterocyclic compounds as pesticides |
| JP2019500352A (ja) * | 2015-12-10 | 2019-01-10 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病の治療方法 |
| JP2021028331A (ja) * | 2015-12-10 | 2021-02-25 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病の治療方法 |
| JP2021042211A (ja) * | 2015-12-10 | 2021-03-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病の治療方法 |
| JP7025508B2 (ja) | 2015-12-10 | 2022-02-24 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病の治療方法 |
| JP7053760B2 (ja) | 2015-12-10 | 2022-04-12 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病の治療方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007310897A1 (en) | 2008-05-02 |
| MX2009003892A (es) | 2009-04-23 |
| IL197397A0 (en) | 2009-12-24 |
| US20100029685A1 (en) | 2010-02-04 |
| CA2667545A1 (en) | 2008-05-02 |
| WO2008049864A1 (en) | 2008-05-02 |
| EP2079734A1 (en) | 2009-07-22 |
| NO20091977L (no) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010507619A (ja) | オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用 | |
| US8017631B2 (en) | Oxadiazole derivatives and their medical use | |
| JP2010507619A5 (enExample) | ||
| US8637510B2 (en) | Morpholinothiazoles as alpha 7 positive allosteric modulators | |
| JP2010523654A (ja) | 複素環化合物およびその使用方法 | |
| JP2020507582A (ja) | キナーゼ阻害剤としてのアミノトリアゾロピリジン | |
| JP2013515032A (ja) | 二置換ヘテロアリール縮合ピリジン類 | |
| JP2013515033A (ja) | オレキシン受容体アンタゴニストとしてのジアザ−スピロ［５．５］ウンデカン類 | |
| JP2012501317A (ja) | トリアゾール誘導体、及びそのニコチン性アセチルコリン受容体モジュレーターとしての使用 | |
| JP2022519770A (ja) | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 | |
| JP2008517032A (ja) | 新規なジアザ二環式アリール誘導体及びその医薬用途 | |
| US20070293497A1 (en) | 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease | |
| JP2009518357A (ja) | 新規なジアザ二環式アリール誘導体及びそれらの医学的使用 | |
| JP2021523102A (ja) | スピロピペリジン系ニコチン性アセチルコリン受容体アロステリック調節剤 | |
| KR20090069183A (ko) | 옥사디아졸 및 티아디아졸 화합물 및 니코틴성 아세틸콜린 수용체 조절제로서의 이들의 용도 | |
| CN114786771A (zh) | 作为lpa受体2抑制剂的喹唑啉衍生物 | |
| US12344600B2 (en) | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | |
| HK1137757A (en) | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators | |
| CN101166735A (zh) | 新颖的二唑衍生物及其医药应用 | |
| JP2008521776A (ja) | コリン作動性リガンドとしての新規なジアザ二環式アリール誘導体 | |
| US8383658B2 (en) | Isoxazole based neuronal nicotinic receptor ligands and methods of use | |
| CN101213182A (zh) | 作为α7烟碱性受体调节剂的噻吩-2-甲酰胺 | |
| HK1117503A (en) | Novel oxadiazole derivatives and their medical use | |
| EA047337B1 (ru) | Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора | |
| HK40068822A (en) | Quinazoline derivatives as lpa receptor 2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100614 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100614 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20120823 |